Failure

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Retrieved on: 
Thursday, March 17, 2022
Company, Private Securities Litigation Reform Act, Therapy, Public health, NYSE, SEC, Research, Cancer, CEO, Failure, Safety, Union for International Cancer Control, COVID-19, GLOBE, R, RFL, Annual report, Pharmaceutical industry, Health insurance

NEWARK, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and six months ended January 31, 2022.

Key Points: 
  • NEWARK, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and six months ended January 31, 2022.
  • The end of our second fiscal quarter marks a beginning for the reorganized and focused Rafael Holdings with Bill Conkling assuming the responsibilities of Chief Executive Officer from Ameet Mallik as of February 1, 2022.
  • Our revenues for the second quarter of fiscal 2022 amounted to $1.1 million, compared to revenues of $1.0 million in the second quarter of fiscal 2021.
  • Our revenues for the first six months of fiscal 2022 amounted to $2.1 million, compared to revenues of $2.0 million in the first six months of fiscal 2021.

FINRA Issues Reminder About the Scope of Chief Compliance Officer Supervisory Liability

Retrieved on: 
Thursday, March 17, 2022
Banking, Legal, Professional Services, Finance, Compliance, California Regulatory Notice Register, CEO, Wells notice, Notice, SEC, Industry, Education, CCO, C, Failure, Financial adviser, FINRA

FINRA today issued a Regulatory Notice reminding member firms about the scope of broker-dealer chief compliance officer (CCO) supervisory liability under FINRA rules.

Key Points: 
  • FINRA today issued a Regulatory Notice reminding member firms about the scope of broker-dealer chief compliance officer (CCO) supervisory liability under FINRA rules.
  • Chief compliance officers play an important role in facilitating compliance by promoting strong practices that protect investors and market integrity.
  • That does not automatically make them supervisors, subject to FINRAs supervisory requirements, said Jessica Hopper, Executive Vice President, Enforcement.
  • The Notice discusses the scope of the Supervision Rule (3110), the CCOs role and how FINRA assesses a CCOs liability under Rule 3110.

ALYI Participates In SXSW Transportation Track Featuring Transportation Secretary Pete Buttigieg

Retrieved on: 
Thursday, March 17, 2022
Company, Formula, Contract, Transport, EV, Ecosystem, Failure, Learning, Electricity, GLOBE, SXSW, News, Private Securities Litigation Reform Act, OTC Markets Group, Risk management

Dallas, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Alternet Systems, Inc. (OTC Pink: ALYI) today announced the company is participating in the SXSW Transportation Track in Austin, Texas featuring Transportation Secretary Pete Buttigieg .

Key Points: 
  • Dallas, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Alternet Systems, Inc. (OTC Pink: ALYI) today announced the company is participating in the SXSW Transportation Track in Austin, Texas featuring Transportation Secretary Pete Buttigieg .
  • "We are representing our EV initiative in Africa and learning about the latest in global transportation initiatives, said CEO Randell Torno.
  • ALYI is building an EV Ecosystem that includes organic and partner solutions for all aspects of the growing EV transportation system.
  • ALYIs SXSW participating is centered around ALYIs interest in Formula E. ALYI has worked closely with a Kenyan race event business named East African Grand Prix (EAGP).

Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc.

Retrieved on: 
Thursday, March 17, 2022
Private Securities Litigation Reform Act, Company, Entourage effect, Fungus, Organization, Letter, Psychotherapy, Therapy, Partnership, Form, Risk, Forward-looking statement, University, Research, SEC, Failure, CEO, U.S. Securities and Exchange Commission, MOH, Security (finance), Technology, Media, TPIA, Psilocybin, GLOBE, Ministry, EI, Cannabis, OTC, Acquisition, OTC Markets Group, Regional health authority, CSE, Pharmaceutical industry, Health

The terms of the original agreement call for Havn Life Sciences to supply Mycotopia Therapies with naturally-derived psilocybin.

Key Points: 
  • The terms of the original agreement call for Havn Life Sciences to supply Mycotopia Therapies with naturally-derived psilocybin.
  • In December 2021 Mycotopia Therapies Inc. announced it had entered into a letter of intent regarding a potential acquisition of botanical psilocybin pioneer, Ei.Ventures.
  • Mycotopia Therapies is focused on the research, development, and commercialization of novel therapeutics based on naturally-derived psilocybin.
  • Performing most of its research in Jamaica, where psilocybin is legal, Mycotopia Therapies is focused on mushroom and psychedelic opportunities.

Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism

Retrieved on: 
Thursday, March 17, 2022
Chronic kidney disease, Urine, Risk, American Society for Bone and Mineral Research, Population, Parathyroid hormone, Hypercalciuria, Osteoporosis, Kidney, IND, Hypoparathyroidism, Phosphorus, Serum, Endocrinology, Half-life, Woman, Failure, Food, Tissue, Calcium, Quality of life, Safety, Annual general meeting, Twitter, Society, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Union, Osteopenia, PTH, Acromegaly, FDA, Blood, Patient, Pharmaceutical industry, Dietary supplement

Bone biomarker data from this trial also leads us to believe that AZP-3601s targeted mechanism of action may preserve bone integrity.

Key Points: 
  • Bone biomarker data from this trial also leads us to believe that AZP-3601s targeted mechanism of action may preserve bone integrity.
  • These are important benefits as 26% of patients with hypoparathyroidism have chronic kidney disease and 17% have already developed osteopenia or osteoporosis.
  • Clinical manifestations of hypoparathyroidism impact a large number of tissues and organ systems, and in particular, the kidneys and bone.
  • 17% of patients with hypoparathyroidism have osteopenia or osteoporosis and 53% are peri- or postmenopausal women with an increased risk of developing osteoporosis.

Clever Leaves Appoints William Muecke to Board of Directors

Retrieved on: 
Thursday, March 17, 2022
Pandemic, LinkedIn, NASDAQ, Cornell University, Risk, Forward-looking statement, 100,000, Growth, Donaldson, THC, ESG, SEC, Chemistry, Perception, Lists of disasters, CEO, Failure, API, Xi, Private Securities Litigation Reform Act, Donaldson, Lufkin & Jenrette, Industry, Goal, CBD, Disclosure, Time, COVID-19, BOCA, GLOBE, Goldman, Program, Cannabis, Weather, History

Commenting on his appointment, Muecke said: With Clever Leaves ability to leverage its cost-efficient business model into significant commercial execution, I believe its very well-positioned in the global pharmaceutical cannabinoid market.

Key Points: 
  • Commenting on his appointment, Muecke said: With Clever Leaves ability to leverage its cost-efficient business model into significant commercial execution, I believe its very well-positioned in the global pharmaceutical cannabinoid market.
  • For more information, please visit https://cleverleaves.com/en/home/ and follow Clever Leaves on Twitter ( @clever_leaves ) and LinkedIn ( https://www.linkedin.com/company/clever-leaves ).
  • Additional information concerning certain of these and other risk factors is contained in Clever Leaves most recent filings with the SEC.
  • All subsequent written and oral forward-looking statements concerning Clever Leaves and attributable to Clever Leaves or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above.

Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance

Retrieved on: 
Thursday, March 17, 2022
Private Securities Litigation Reform Act, Company, Dyskinesia, LLP, Mission statement, Migraine, Compliance, Adult, Central nervous system, CNS, Torticollis, Failure, KPMG, Nasdaq, Epilepsy, GLOBE, KPMG LLP, ADHD, Central nervous system disease, Annual report, Depression, Patient, Pharmaceutical industry, PD

Today, Supernus notified the Nasdaq Listing Qualifications Department that it is not in compliance with the filing requirement under Nasdaq Rule 5250(c)(1) due to its failure to timely file its Annual Report.

Key Points: 
  • Today, Supernus notified the Nasdaq Listing Qualifications Department that it is not in compliance with the filing requirement under Nasdaq Rule 5250(c)(1) due to its failure to timely file its Annual Report.
  • Supernus currently anticipates filing its Annual Report on or before April 4, 2022 and thereby regaining compliance with the filing requirement.
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
  • These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations.

Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer

Retrieved on: 
Thursday, March 17, 2022
Mental Health, Other Health, Health, Other Technology, Technology, Adoption, Microsoft, Risk, Bejeweled Blitz, Proxy, PopCap Games, Sale, Plant, Form, Government budget balance, Forward-looking statement, Lists of video games, 100,000, Patient, Register, Social, Glu Mobile, XV, Research, SEC, General manager, Medicine, Failure, CEO, Communication, Suite, Entrepreneurship, Xbox Live Arcade, Vii, Xi, ALL, Name, SCS, Industry, Technology, Prospectus, Electronic Arts, THE, Mergers and acquisitions, Securities Act of 1933, Tripura Merger Agreement, Nasdaq, Registration statement, COVID-19, Magic, Brain, Acquisition, IP, Management, Video game, Security (finance), Risk management, Yolo Akili, Taunting

Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer.

Key Points: 
  • Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer.
  • Jon is a proven executive and top-tier innovator in the video game industry, and we are thrilled to have his vision and expertise on the team, said Eddie Martucci, Co-Founder and Chief Executive Officer of Akili.
  • Im looking forward to bringing even more joy and magic to the Akili product experience as we grow, said Jon David, Chief Product Officer at Akili.
  • Neither Akili nor SCS gives any assurance that either Akili or SCS, or the combined company, will achieve its expectations.

PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer

Retrieved on: 
Thursday, March 17, 2022
Science, Other Science, Biotechnology, Research, General Health, Health, Clinical Trials, Other Health, Private Securities Litigation Reform Act, Risk, PopCap Games, Register, Research, SEC, Environment, Medicine, CEO, Suite, Vii, SCS, Technology, Twitter, Securities Act of 1933, Tripura Merger Agreement, Nasdaq, LSE, Annual report, Proxy, U.S. FDA, Plant, Sale, Xi, Industry, Biology, Brain, Cancer, PRTC, Therapy, Form, Forward-looking statement, Multimedia, Social, Failure, Name, ALL, Prospectus, Electronic Arts, Magic, FDA, Patient, Registration statement, Axis, IP, Adoption, Microsoft, Company, Bejeweled Blitz, Government budget balance, Lists of video games, 100,000, Glu Mobile, XV, General manager, Communication, Xbox Live Arcade, Entrepreneurship, THE, Mergers and acquisitions, COVID-19, Degenerative disease, BIG, PureTech Health, Acquisition, Management, Video game, Security (finance), Risk management, Yolo Akili, Taunting, Akili, PureTech Health, AKILI, PURETECH HEALTH

View the full release here: https://www.businesswire.com/news/home/20220317005363/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220317005363/en/
    PureTech Founded Entity, Akili, announced the appointment of Jon David as Chief Product Officer.
  • The full text of the announcement from Akili is as follows:
    Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer
    BOSTON, Mass.
  • March 17, 2022 Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer.
  • Im looking forward to bringing even more joy and magic to the Akili product experience as we grow, said Jon David, Chief Product Officer at Akili.

Ancora Issues Open Letter to the Board of Directors of Everbridge Regarding the Urgent Need to Explore Strategic Alternatives

Retrieved on: 
Thursday, March 17, 2022
Banking, Professional Services, Finance, Company, Risk, CEM, Sale, Leadership, Marketing, Shareholder, RSU, Growth, Glassdoor, Board, Culture, Ownership, M&A, Research, Failure, SVP, Industry, Technology, Review, Intention, Anvil, Everbridge, Enterprise value-to-sales ratio, R, Form 4, Efficiency, IPO, Acquisition, History, Management, Auction, Sales, Brickley

On the Companys Q4 2021 earnings call, Everbridge called out the need to focus on integrating its acquired technologies.

Key Points: 
  • On the Companys Q4 2021 earnings call, Everbridge called out the need to focus on integrating its acquired technologies.
  • This is an extremely challenging task to take on while in the public market, and one we feel Everbridge is ill-equipped to navigate.
  • Everbridge does not disclose contributions from M&A, seemingly obscuring that the Company has been paying higher prices to acquire growth.
  • We believe Everbridge is a valuable strategic asset addressing a mission critical need in a large market with vast upside potential.